Accessibility Menu
Compass Pathways logo

Compass Pathways

(NASDAQ) CMPS

Current Price$12.52
Market Cap$1.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-57%
5 Year-65%
1 Year+216%
1 Month+8%
Compass Pathways last closing stock price
MetricPriceDate
Last closeUSD 12.432026-07-16
Compass Pathways stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.6%USD 13.602026-07-09
1 month+8.18%USD 11.492026-06-16
3 month+86.64%USD 6.662026-04-17
Year to date+80.14%USD 6.902025-12-31
1 year+216.28%USD 3.932025-07-16
3 year+36.14%USD 9.132023-07-17
5 year-64.51%USD 35.022021-07-16
Since inception-57.14%USD 29.002020-09-18

Compass Pathways Financials at a Glance

Market Cap

$1.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$178.80M

EPS (TTM)

-$3.16

P/E Ratio

-3.94

Dividend

$0.00

Beta (Volatility)

1.45 (Average)

Price

$12.52

Volume

3,286,508.523

Open

$12.47

Previous Close

$12.43

Daily Range

$12.02 - $13.04

52-Week Range

$3.83 - $15.40

Estimated Earnings Date

Jul 30, 2026

CMPS News

Hands holding some pills from a bottle

5 Best Psychedelic Stocks for 2026 and How to Invest

Keith SpeightsJul 10, 2026
GettyImages-2236718581-601x347-d787695

Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About

Jeff SiegelApr 23, 2026
psychedelic episode

Why Compass Pathways Stock Rocketed 40% Today

Howard SmithApr 20, 2026
GettyImages-1768385129

Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar

Matthew BenjaminApr 20, 2026
GettyImages-2195313809

Stock Market Today (LIVE): Oil Spikes as U.S. Seizes Iranian Ship; Psychedelic Drugs on the Fast Track

The Motley Fool TeamApr 20, 2026
Stocks higher with yellow arrows

Why Did Compass Pathways Stock Rocket Higher Today?

Howard SmithFeb 17, 2026
Foolcom-Featured.png

Compass (CMPS) Q2 Loss Improves 27%

Motley Fool Markets TeamAug 1, 2025
smart-investor-with-wall-street-journal-picking-stocks-to-buy

These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?

Cory RenauerJul 20, 2025
Page 1

CMPS: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Compass Pathways

COMPASS Pathways develops therapies for people with severe mental health conditions. Its main product, COMP360, targets depression that does not respond to standard treatments. The company aims to help patients who have not found relief with existing options.

Products and Services

  • COMP360 Psilocybin Therapy: A pharmaceutical-grade psilocybin treatment for depression and post-traumatic stress disorder; 0% of revenue as of 2025.
  • Digital Support Tools: MyPathfinder app and online platforms for patient education and therapy preparation; 0% of revenue.
  • Clinical Research Partnerships: Collaborations with academic centers for clinical trials and training; 0% of revenue.
  • Investigator-Initiated Studies: Support for external research into new uses for COMP360; 0% of revenue.

Growth and Expansion

  • Completed Phase IIb and pivotal Phase 3 trials for COMP360 in depression (2023-2025).
  • Launched and completed a Phase II trial for COMP360 in post-traumatic stress disorder in 2024; finalized design and regulatory preparation for a Phase 2b/3 trial, with FDA IND enabling initiation in January 2026.
  • Formed partnerships with U.S. healthcare providers like Greenbrook and Hackensack Meridian Health (2024-2025).
  • Invested in neuroscience company Delix Therapeutics in March 2020 and November 2025.
  • Established Centers of Excellence with academic partners for research and training (2023-2025).

What Makes COMPASS Pathways Stand Out

The company focuses on combining drug therapy with psychological support in controlled settings. It holds patents for its psilocybin formulation and delivery methods, protecting its approach until at least 2042. Strategic partnerships and research centers help it prepare for future commercial delivery and expand its clinical reach.

Five Things You Need to Know

  • No revenue was reported for 2023, 2024, or 2025.
  • Operating loss was $41 million in QQ3 2025, improving 15.4% from QQ3 2024.
  • Net loss was $138 million in QQ3 2025, up from $39 million in QQ3 2024.
  • Cash and cash equivalents were $149.6 million as of December 31, 2025.
  • 156 full-time employees in 2025, with 101 in research and development roles.

Bottom Line

COMPASS Pathways is developing new mental health treatments but has not yet generated revenue. Its focus remains on clinical trials, partnerships, and preparing for future commercial launch.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

156

CEO

Kabir Kumar Nath, MBA

Website

compasspathways.com

Headquarters

London, CH W1F 0DQ, GB

CMPS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-150.89%

Return on Capital

N/A

Return on Assets

-33.62%

Earnings Yield

-25.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

134.92M

Volume

3.29M

Avg. Volume

4.91M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$172.33M

EBITDA

-$176.60M

Operating Cash Flow

-$159.52M

Capital Expenditure

$0.00

Free Cash Flow

-$159.52M

Cash & ST Invst.

$466.01M

Total Debt

$2.83M

Compass Pathways Performance Analysis

Compass Pathways annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Compass Pathways sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Compass Pathways annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.1620.2%
20232023-12-31USD -2.338.1%
20242024-12-31USD -2.30-1.3%
20252025-12-31USD -3.0934.2%
Compass Pathways sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-70.8%
Q32025-09-30-251.2%
Q42025-12-3130.6%
Q12026-03-3170.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.75M

N/A

Employees

156

N/A

Net Income

$91.20M

+610.5%

EBITDA

$92.66M

+666.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$466.01M

+79.2%

Total Debt

$2.83M

-91.2%

Accounts Receivable

$15.13M

-51.7%

Inventory

$0.00

N/A

Long Term Debt

$779.00K

-96.4%

Short Term Debt

$2.05M

-79.9%

Return on Assets

-33.62%

N/A

Return on Invested Capital

-45.60%

N/A

Free Cash Flow

-$47.94M

-5.0%

Operating Cash Flow

-$47.94M

-5.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KALVKalVista Pharmaceuticals, Inc.
$27.00+0.00%
AVNSAvanos Medical, Inc.
$24.98+0.08%
TALKTalkspace, Inc.
$5.22+0.09%
SNDASonida Senior Living, Inc.
$41.70+3.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$67.07-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.44-0.00%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.99+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.36-0.05%

Questions About CMPS

What is the current price of Compass Pathways?

Compass Pathways is trading at $12.65 per share.

What is the 52-week range for Compass Pathways?

Over the past 52 weeks, Compass Pathways has traded between $3.83 and $15.40.

How much debt does Compass Pathways have?

As of the most recent reporting period, Compass Pathways reported total debt of $53.31M.

How much cash does Compass Pathways have on hand?

Compass Pathways reported $466.39M in cash and cash equivalents in its most recent financial results.

What is Compass Pathways’s dividend yield?

Compass Pathways does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services